Research and Markets (http://www.researchandmarkets.com/research/h4zm8f/ocular)
has announced the addition of the "Ocular
Hypertension - Pipeline Review, H2 2015" report to their
offering.
This report provides comprehensive information on
the therapeutic development for Ocular Hypertension, complete with
comparative analysis at various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type, along with latest updates, and featured news and press
releases. It also reviews key players involved in the therapeutic
development for Ocular Hypertension and special features on late-stage
and discontinued projects.
The report enhances decision
making capabilities and help to create effective counter strategies to
gain competitive advantage. It strengthens R&D pipelines by identifying
new targets and MOAs to produce first-in-class and best-in-class
products.
Companies Involved in Therapeutics Development
- Aerie Pharmaceuticals, Inc.
- Allergan Plc
- Amakem NV
- Asahi Kasei Pharma Corp.
- Bausch & Lomb Incorporated
- Can-Fite BioPharma Ltd.
- F. Hoffmann-La Roche Ltd.
- Inotek Pharmaceuticals Corporation
- Merck & Co., Inc.
- NicOx S.A.
- Ocular Therapeutix, Inc.
- Ono Pharmaceutical Co., Ltd.
- Otsuka Holdings Co., Ltd.
- Sanofi
- Santen Pharmaceutical Co., Ltd.
- Senju Pharmaceutical Co., Ltd.
- Sylentis S.A.
Drug Profiles
- (bimatoprost + brimonidine tartrate)
- (carteolol hydrochloride + latanoprost)
- (dorzolamide hydrochloride + latanoprost)
- (latanoprost + trabodenoson)
- (tafluprost + timolol maleate)
- AMA-0076
- AR-13324
- ATS-8535
- bamosiran
- bimatoprost SR
- DE-117
- Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension
- latanoprost
- latanoprost SR
- latanoprostene bunod
- lomerizine
- NCX-470
- NCX-667
- ONO-9054
- OPA-6566
- piclidenoson
- RO-5093151
- SAR-366234
- SNJ-1656
- tafluprost
- trabodenoson
- travoprost SR
For more information visit http://www.researchandmarkets.com/research/h4zm8f/ocular
View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005473/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector:
Pharmaceuticals,
Optical
